Biologic therapies in the vasculitides.
Biologic therapies in the vasculitides.
复制标题
血管炎的生物疗法。
DOI：
10.1097/00002281-200301000-00002
复制
发表时间：
2003
影响因子：
5.1
通讯作者：
Sneller,MichaelC
中科院分区：
文献类型：
--
作者：
Langford,CarolA;Sneller,MichaelC
单抗和重组DNA技术已经导致了能够直接针对免疫反应的选定成分的生物疗法的发展。随着人们对血管炎症机制认识的不断深入，生物制剂在血管疾病中的安全性和有效性正受到越来越多的研究。通过针对血管炎发病机制中涉及的特定效应机制，这些药物可能提供一种毒性较低的诱导缓解和减少复发的方法。然而，研究血管炎的生物疗法必须谨慎，因为可能会对疾病活动性和疾病特异性毒性产生意想不到的影响。检查这些病原体的研究必须认识到活动性脉管炎可能危及器官或生命，以及目前存在有效的治疗方法。在研究背景下，对治疗血管疾病的生物制剂的调查也可能为这些综合征的发病机制提供重要的见解。
Monoclonal antibody and recombinant DNA technologies have led to the development of biologic therapies capable of directly targeting selected components of the immune response. With the steady expansion of knowledge regarding the mechanisms of vascular inflammation, the safety and efficacy of biologic agents in the vasculitic diseases are being increasingly investigated. By targeting specific effector mechanisms involved in the pathogenesis of vasculitis, these agents may provide a less toxic means of inducing remission and lessening relapse. However, the study of biologic therapies in the vasculitides must be approached with caution, as unanticipated effects on disease activity and disease-specific toxicities can occur. Studies to examine these agents must recognize the potential for active vasculitis to be organ-or life-threatening as well as the current existence of effective therapies. In the research setting, investigation of biologic agents in the treatment of vasculitic diseases may also provide important insights into pathogenesis of these syndromes.